Page 6 - Pharma Companies

Akums Drugs and Pharmaceuticals sets IPO price band at Rs 646-679 per share

Contract manufacturer Akums Drugs plans expansion; targets higher margins

Torrent Pharma Q1FY25 results: Net profit up 21%, revenue rises 10%

Revenues in the USA market, however, were down by 12 per cent at Rs 259 crore, falling from Rs 293 crore reported in Q1 FY24

Pharma companies on track with QR codes to combat counterfeit drugs

Firms term DCGI move 'positive' as it aims at ensuring patient safety

Dr. Reddy's Laboratories joins race to bring new GERD drug to India

Dr. Reddy's will market Vonoprazan tablets under its own brand Vono, and it will be available in two strengths, 10 mg and 20 mg

Cipla receives additional Rs 773.44 crore tax demand from income tax office

Cipla's share price declined by 0.56 per cent, ending the day's trade at Rs 1,507.50 apiece on the BSE

Centre, states must collaborate for global investment in India: Mukesh Aghi

Mukesh Aghi talks about the recent Lok Sabha elections, expectations from the coming Budget, changes in India's regulatory environment.

Glenmark Pharmaceuticals to sell 7.84% stake in Glenmark Life Sciences

The specific price and date of the offer for sale will likely be announced in the future

AstraZeneca to invest Rs 250 crore in expanding its GITC in Chennai

This will be the company's largest GCC in the world. This is a monumental addition by the company, joining other global giants like Hitachi Energy in establishing their biggest GCCs in Chennai

New product launches may continue to fuel GSK Pharma's robust growth

GSK Pharma's recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding

How Alkem's 83-year-old founder is remaking India's 4th-largest pharma firm

Hailing from Okari, a remote village in Jehanabad district of Bihar, Singh and his brother, Samprada, moved to Mumbai in 1973 to start Alkem Laboratories with a seed capital of Rs 5 lakh

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Pharmaceutical companies prepare to comply with ethical marketing code

Companies must commit that they comply with a code against unethical marketing of drugs

Why did investors dump Marksans Pharma shares post Q4 results? Know here

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

AstraZeneca Q4 results: Net profit jumps 128%, revenue rises 34.59%

Strategic collaborations played a crucial role in AstraZeneca's achievements, particularly in enhancing diagnostic capabilities and treatment outcomes

Cipla rallies 4% on US FDA approval to market Lanreotide injection

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

State regulators asked to withdraw marketing of cancer drug Olaparib

Manufacturer AstraZeneca Pharma India says its study shows drug may have detrimental effect

AstraZeneca aims to grow its total revenue by 75% to $80 bn by 2030

The Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier expected to launch at least 15 new medicines between 2023 and 2030

Indian pharma firms supplied 47% of all generic prescriptions in US in 2022

Indian pharmaceutical companies also accounted for a lower but important share of biosimilar production, manufacturing 15 per cent of biosimilar volume used by US patients in 2022

Mankind Pharma open to acquisitions; board okays Rs 7,500 cr fundraise

The drug maker was reportedly interested in buying private equity (PE) firm Advent International's stake in Mumbai-based biopharma firm Bharat Serums and Vaccines (BSV)

Piramal Pharma open to partnerships in OTC; eyes further debt reduction

Piramal said that they are focusing on organic growth across all their verticals - OTC business in India, complex hospital generics, and the Contract Development and Manufacturing (CDMO) business